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II. Abstract 
Obesity prevalence in the United States continues to increase and is associated with 
health consequences such as type 2 diabetes, hypertension, atherosclerosis, and hyperlipidemia. 
Among many contributing factors to obesity, fructose may be one of the major reasons as it 
disrupts the antioxidant system thereby resulting in an accumulation of reactive oxidative species 
and leading to obese conditions. The enzyme, isocitrate dehydrogenase 2 (IDH2), reduces 
nicotinamide adenine dinucleotide phosphate from the TCA Cycle, hence might be implicated 
with not only energy metabolism but also cellular redox homeostasis. Therefore, the hypothesis 
was that IDH2 deficiency in mice would exacerbate hepatic lipid metabolism in response to 
fructose intervention. The study consisted of a total of 24 IDH2 knockout female mice and their 
background strain (C57BL/6N) mice; the animals were assigned to either fructose or control diet 
group. After intervention of fructose over six weeks (34%; v/v), tissue weight, liver expression 
of lipogenesis gene (SREBP-1, SCD1, FAS, and DGAT2), and liver expressions of lipolysis 
genes (AMPK, SIRT1, and PPARɑ) were measured. There was a significant increase in visceral 
fat, while the body mass remained the same. Further, there was a trend of increase in expression 
of lipogenesis genes, whereas no change was shown in lipolysis gene expression in IDH2 mice 
fed fructose. In conclusion, even though changes in visceral fat mass were statistically significant 
in IDH2 deficient mice, hepatic lipid metabolism did not support the phenotypes in this study. 
Additional studies with larger sample size are warranted to find a potential link between IDH2 
and increase in visceral fat accumulation.   
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III. LITERATURE REVIEW 
 
Obesity Prevalence and Chronic Illness Association 
Obesity is a state of excess accumulation of fat tissue, which occurs through an increase 
of size in adipocytes or increase of fat cells. It can be caused by an imbalance between energy 
intake and expenditure (1). Overweight and obesity have become a major problem in multiple 
Western countries since the 1950s, and their prevalence has been increasing steadily (2). Indeed, 
in the past 35 years, obesity prevalence has doubled worldwide and, in the United States, there is 
an obesity prevalence of 38.3% for women and 34.3% for men (3). Interest in the prevention of 
obesity has been on the rise since it is one of the most important risk factors for other diseases 
such as hypertension, type 2 diabetes, hyperlipidemia, and nonalcoholic fatty liver disease 
(NAFLD) (4). For example, the prevalence rate of NAFLD increases with the elevation of body 
mass index, a marker of obesity (5). Additionally, the medical cost of overweight-related 
diseases such as obesity or type 2 diabetes has tripled since the 1980s (6). Knowing the medical 
implications of obesity, it is critical to understand what factors play a role in causation in the 
development of obesity and abnormal increase of adipocytes. 
 
Obesity Risk Factors 
Factors implicated in the development of obesity include educational level, obesity trends 
within families, the promotion of a sedentary, high-fat, and high-sugar intake. According to the 
National Health and Nutrition Examination Survey (NHANES), as women’s educational level 
decreased, the trend for obesity increased. Additional risk factors for obesity are social 
determinants. Socioeconomic conditions (e.g., concentrated poverty) also play a part in obesity 
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trends. Examples are residential segregation, access to health care services, transportation 
options, availability of resources to meet daily needs, and social support (7). Not surprisingly, 
genetics and ethnicity play a major role in obesity prevalence as well. For instance, according to 
the NHANES study, the prevalence of obesity was lowest among non-Hispanic Asian adults 
(11.7%), followed by non-Hispanic white (34.5%), and Hispanic (42.5%). Non-Hispanic black 
(48.1%) adults had the highest level of obesity rates (7). 
As expected, diet also plays a huge role in an individual developing obesity. At the 
surface level, a high ratio of caloric input verse caloric output will cause an increase in weight. 
Consuming more calories than the individual expends will cause an increase in adipocyte size, 
leading to obesity. Additionally, the type of diet one consumes plays a factor into obesity. A 
high-fat and high-sugar based diet, along with excess calories and poor physical activity, will 
lead to a gain in weight and eventually obesity. Common food tendencies that fall into this 
category include meals eaten out, processed or fast foods, and sugary drinks (8). 
Beverages containing high-fructose corn-syrup are the most common sugary drinks in 
United States today. In 2011-2014, 63% of youth and 49% of adults drank sugary drinks on any 
given day (9). On average, U.S. youth consume 143 calories from sugary drink and U.S. adults 
consume 145 calories from sugary drinks on a given day (9). High fructose corn-syrup is a 
commonly used substitute for sucrose, and is found in beverages, baked goods, canned fruits, and 
dairy products. High fructose corn-syrup is the major source of calories in these products, and 
therefore high fructose corn-syrup is the nation's major source of artificial sweetener and dietary 
fructose (10). Knowing the close correlation between obesity and chronic illnesses, it is 
beneficial to look into factors that contribute to increasing obesity rates, particularly fructose 
given its predominant use in processed foods. 
 7 
 
Health Implications of Fructose 
Diets high in sugar may promote the development of metabolic diseases. Recent 
epidemiological studies have strengthened pre-clinical and clinical observations; for instance, 
Mattei et al., showed that consumption of sugar sweetened beverages (e.g., instant sugary 
powder mix beverages and carbonated non-diet beverages) increased plasma triglycerides, waist 
circumference, and metabolic syndrome (11). Similarly, increased frequency of sugar sweetened 
beverage intake was positively associated with increased proportion of visceral to subcutaneous 
abdominal adipose tissues (12). Particularly, fructose is often added in processed foods such as 
soft drinks, canned fruits, and dairy products (1), and its intake over the years has increased thus 
it may be a major contributor for the increase in the overweight and obese population (12). Not 
limited to obesity per se, chronic diseases (e.g., NAFLD, type 2 diabetes, and hyperglycemia) are 
also associated with a high-fructose, high-fat diet (13). In particular, fructose is known to induce 
hypertension (14) and, potentially, lipogenesis (15)  hence increasing the potential for the 
development of hyperlipidemia and cardiovascular diseases. 
There are several mechanisms proposed with regard to fructose and its implications to 
chronic diseases. To be specific, fructose directly affects lipid and carbohydrate metabolism and 
indirectly promote positive energy balance, thereby resulting in dysregulation of energy 
homeostasis (16). Fructose is transported into cells via GLUT5, which is highly expressed in the 
liver, small intestine, and pancreas (15); this transporter is specific to fructose and the aid of 
digestion (20). Hepatocytes have high fructose extraction rates thus, virtually an entire ingested 
fructose molecule can be metabolized in the liver (21). In the hepatocytes, fructose is 
phosphorylated to fructose-1-phosphate, initiating the breakdown of fructose (also known as 
fructolysis), eventually forming pyruvate and subsequently acetyl-CoA, a primary substrate for 
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lipogenesis (22). While glucose and fructose metabolism both yield acetyl-CoA, glucose-derived 
acetyl-CoA is tightly regulated by insulin (21) and by feedback inhibition of glycolytic flux by 
adenosine triphosphate (ATP) generated from glycolysis (22). In contrast, acetyl-CoA generation 
via fructolysis continues uninterrupted, and is not ATP-sensitive (22). Thus, unabated fructolysis 
leads to unabated lipogenesis (15, 22). 
An additional mechanism of fructose-mediated obesity is closely related to a disruption 
of the antioxidant defense system (17). In this, antioxidant enzymes are susceptible to post-
translational modification (e.g., glycation) in which kinetic activities can be inhibited [e.g., 
nicotinamide adenine dinucleotide phosphate (NADP+)-dependent isocitrate dehydrogenase, 
(IDH2); (18)]. Therefore, it is possible that fructose-induced glycation of enzymes may lead to 
the perturbation of the cellular antioxidant defense system and accumulation of reactive oxygen 
species (ROS), subsequently resulting in obesity conditions. In that regard, nicotinamide adenine 
dinucleotide phosphate, reduced (NADPH) is critical because oxidized glutathione (i.e., 
endogenous cellular antioxidant) is regenerated via NADPH-consuming glutathione reductase 
and peroxidase systems (19). 
 
Summary and Study Hypothesis 
Fructose may be one of the major factors for high prevalence of obesity in the United 
States due to disruption of hepatic lipid metabolism via multiple mechanisms. Particularly, it 
causes post-translational modification of key metabolic enzymes including IDH2; this 
mitochondrial enzyme catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate 
with concurrent reduction of NADP+ to NADPH. Since NADPH is used as a cofactor of 
glutathione reductase to maintain the redox systems, impaired IDH2 activity, either by 
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environmental (fructose) or genetic mutation (e.g., single nucleotide polymorphism), may disrupt 
hepatic lipid metabolism. Therefore, it is hypothesized that lack of IDH2 may exacerbate 
dysregulation of hepatic lipid metabolism that is induced by fructose exposure.  
  
IV. MATERIALS AND METHODS 
 
Animals and study diets 
A total of 24 female IDH2 knockout (KO) mice and their background strain (C57BL/6N) 
mice [wild type (WT)] were assigned into either a fructose group or a control group: WT control 
group (WT CON, n=6), WT fructose group (WT FRU, n=6), IDH2 KO control group (IDH2 
CON, n=6), and IDH2 KO fructose group (IDH2 FRU, n=6). The IDH2 CON and IDH2 FRU 
mice study was carried out at Gyeongnam National University of Science and Technology (Jinju, 
South Korea) and all harvested tissues were shipped to the United States. The WT CON and WT 
FRU mice study was carried out at The University of Arkansas (Fayetteville, Arkansas). Both 
FRU groups were subjected to 34% fructose solution for six weeks to induce obesity phenotypes 
as previously described and validated (16). Control group animals (WT CON and IDH2 CON 
groups) were maintained with deionized water. AIN-76A purified diet was used as a control diet 
and Table 1 shows the detailed dietary composition of the AIN-76A purified diet. All animal 
handling and experiments were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee of the University of Arkansas (Protocol Approval 
Number: 17044). 
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Measurement of body weights, tissue weights, and fat mass 
Body weight was measured once a week, during the six weeks of intervention. After six 
weeks of intervention, the mice were killed by exsanguination via cardiac puncture under 
anesthesia using 2, 2, 2-tribromoethanon (Sigma-Aldrich, St. Louis, MO). Liver, white adipose 
tissue (visceral fat depot) and subscapular brown adipose tissue were harvested and stored in 
RNALater solution (Invitrogen, Carlsbad, CA) at -80°C until analyzed. 
 
RNA extraction and cDNA synthesis 
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instruction. Briefly, total RNA was extracted from 20-30 mg of 
tissues in 0.6 mL lysis buffer containing 1% β-mercaptoethenol. Genomic DNA residues were 
eliminated using the genomic DNA eliminator spin column in the kit. Extracted RNA was 
precipitated using one volume of 70% ethanol, and then collected onto an RNeasy spin column. 
Collected total RNA was washed with a series of washing buffers. Finally, purified RNA 
collected on the spin column membrane was eluted using 30 µL nuclease-free water. The quality 
of extracted RNA was assessed using the conventional A260/280 ratio and A260/230 ratio 
measurement for spectrophotometric (SpectraMax i3x; Molecular Devices, Sunnyvale, CA). 
Isolated RNA (2 µg) was then reversely transcribed using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA) for the cDNA synthesis per the 
manufacturer’s instruction. The cDNA synthesis was performed under the following conditions: 
one cycle at 25°C for 10 min, cycle two at 37°C for 120 min, followed by cycle three at 85°C for 
5 min, and cycle four at 4° C for 1 hr. The cDNA samples were then stored at -80°C until 
analyzed. 
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Quantitative Real Time PCR Analysis for Lipogenic mRNA Expression 
The cDNA was used as a template for the relative quantitation of the following lipogenic 
target genes with predesigned TaqMan gene expression assay kits: sterol regulatory element-
binding protein-1 (SREBP-1), fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1), and 
diglyceride acyltransferase 2 (DGAT2). All reactions were performed in triplicate with the 
StepOnePlus system (Applied Biosystems) in a reaction mixture containing TaqMan Gene 
Expression Mastermix, primers with TaqMan probe (TaqMan Gene Expression Assay; Applied 
Biosystems), and cDNA. Each 20 μL reaction contained 100 ng of cDNA, 2× TaqMan Gene 
Expression Master Mix, and forward and reverse primers with TaqMan probes. Amplification 
was conducted under the following conditions: one cycle at 50°C for 2 min, and 95°C for 10 
min, followed by 40 cycles of denaturation (95°C for 15 s) and annealing (60°C for 1 min). 
Genes of interest were normalized to that of reference genes. Data was analyzed with Step One 
Software (Ver. 2.1; Applied Biosystems) using the ΔΔCT method. 
  
Quantitative Real Time PCR Analysis for Lipolytic mRNA Expression 
Expression of mRNAs was measured by quantitative real time RT-PCR analysis using 
the StepOnePlus system (Applied Biosystems) in a reaction mixture containing TaqMan Gene 
Expression Mastermix, primers with TaqMan probe (TaqMan Gene Expression Assay; Applied 
Biosystems) and cDNA. Briefly, the cDNA was amplified using specific primers for the 
following lipolytic target genes: AMP-activated protein kinase alpha (AMPKα), sirtuin 1 
(SIRT1), and peroxisome proliferator-activated receptor-alpha (PPAR-α). Each 20 μL reaction 
contained 100 ng of cDNA, 2× TaqMan Gene Expression Master Mix, forward and reverse 
primers with TaqMan probe. Amplification was conducted under the following conditions: one 
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cycle at 50°C for 2 min, and 95°C for 10 min, followed by 40 cycles of denaturation (95°C for 
15 s) and annealing (60°C for 1 min). Genes of interest were normalized to that of reference 
genes. All samples were analyzed in triplicate. 
  
Statistical analysis 
All results are expressed as least squares mean ± standard error of means. Gene 
expression data were expressed as relative quantity to the value of WT CON group. Differences 
between the groups were tested using one-way ANOVA followed by multiple comparisons using 
the difference matrix of least squares mean (SAS Institute, Cary, NC, USA). P-values less than 
0.05 were considered statistically different. 
  
V. RESULTS 
 
Effects of IDH2 Deficiency on Visceral Fat Depot 
Body weight, weight gain, and a ratio of tissue weight to body weight were used as 
phenotypic markers of fructose-induced obesity. There was no difference in weight gain 
throughout the study period (p > 0.05; Figure 1). In spite of  no differences in body weight and 
weight gain, a ratio of visceral fat mass to body weight was significantly larger in the IDH2 KO 
groups than those of the WT groups (WT CON vs IDH2 CON, p = 0.04; WT FRU vs IDH2 
FRU, p = 0.0008; Figure 2). No changes were observed in the ratio of brown fat mass to body 
weight (p > 0.05 for all). There was a significant decrease in the ratio of liver weight to body 
weight in IDH2 KO groups (WT CON vs IDH2 CON, p = 0.001; WT FRU vs IDH2 FRU, p = 
0.018; Figure 2). In addition, there was no significant influence of fructose in all parameters 
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between IDH2 CON and IDH2 FRU (i.e., body weight, weight gain, and tissue weight; Figure 
2).  
 
Effects of IDH2 Deficiency on Lipogenesis Genes in Liver 
 Expression levels of key lipogenic genes in liver were measured. Figure 3 shows the 
effects of IDH2 KO on SREBP-1, SCD1, FAS, and DGAT2 mRNA in the liver tissue of mice fed 
with fructose-supplemented water. Overall, the expressions of all four lipogenic genes in IDH2 
CON groups showed no statistical significance when compared to the WT groups, due to large 
variation (p > 0.05 for all; Figure 3). The expression of SREBP-1, however, was higher in IDH2 
FRU group compared to the IDH2 CON group (p = 0.0148). The expression of SCD1 in fructose 
groups was also remarkably higher compared to those of respective control groups (WT CON vs 
WT FRU, p = 0.003; IDH2 CON vs IDH2 FRU, p = 0.02). Moreover, there was a trend of 
increased FAS expression in WT FRU group when compared to WT CON group (p = 0.0627; 
Figure 3). The DGAT2 expression was not found to be statistically significant when the fructose 
groups were compared to control groups (p = 0.27). However, IDH2 KO groups did not show 
change in expression levels of the genes compared to those of WT groups (p > 0.05).  
  
Effects of IDH2 Deficiency on β-oxidation Genes in Liver 
 In order for further investigation of potential mechanisms underlying the phenotypes, 
expression of genes involved in the fatty acid β-oxidative pathway were examined by 
quantitative PCR analysis. There was no difference in the AMPKα expression among the groups 
(p > 0.05; Figure 4). In addition, the expression levels of SIRT1 and PPAR-α were the same for 
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both WT and IDH2 mice. Via measurement of AMPKα, SIRT1, and PPAR-α, there was no 
significant changes in any of the three mRNAs involved in fatty acid β-oxidation (p >0.05).  
 
VI. DISCUSSION 
 Maintaining balanced regulation of lipogenesis and fatty acid β-oxidation pathways are 
crucial as lipid metabolism is highly implicated with multiple metabolic diseases [e.g., obesity, 
type 2 diabetes, and fatty liver disease; (23)]. Not surprisingly, lipid metabolism can be disrupted 
by excessive intake of dietary sugars such as fructose. Thus, fructose is known as one of the 
major causes of obesity-related metabolic syndromes (23). Further, fructose induces 
dysregulation of lipid metabolism via excessive production of ROS in obesity (23). Therefore, 
the study aimed to investigate effects of IDH2 deficiency, a redox regulatory enzyme in 
mitochondria, on fructose-induced dysregulation of hepatic lipid metabolism (i.e., lipogenesis 
and fatty acid β-oxidation).  
 Accumulation of fatty acids is controlled by a lipogenic pathway, in which fatty acids are 
synthesized from acetyl-CoA within the cytosolic fractions of cells. When there is an excess 
consumption of fructose this creates a burden on the metabolic pathway and causes an 
overproduction of acetyl-CoA in the mitochondria (24). The tricarboxylate transport system then 
transports acetyl-CoA into the cytoplasm for fatty acid synthesis from the liver X receptor 
(LXR), SREBP-1, acetyl-CoA carboxylase (ACC), FAS, and SCD1 (24). If there is an increase 
in lipogenesis then malonyl-CoA accumulates; malonyl-CoA is synthesized from acetyl-CoA by 
ACC and used by FAS for fatty acid synthesis (24). In the present study, three representative 
genes were selected of the fatty acid synthesis pathway (i.e., both upstream and downstream 
genes): SREBP-1, FAS, and SCD1. In this, fructose intervention either induced SCD1 gene 
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expression in both WT and IDH2 mice (p = 0.0003 and 0.0223 for WT and IDH2 mice, 
respectively; further fructose intervention resulted a trend of increase in FAS gene expression in 
WT mice, which was somewhat expected (p = 0.0627; Figure 3).  
In addition, the DGAT family (i.e., DGAT1, and DGAT2) has a role in fat deposition by 
be a major gene involved in triglycerides (TG) synthesis (25). Among the DGAT family, DGAT2 
has a more extensive role in TG synthesis than DGAT1 (25, 26). Further, previous findings 
demonstrated that a reduction of DGAT2 expression was positively correlated with a decrease in 
hepatic steatosis (26). In this study, fructose intervention did not result in an increased DGAT2 
gene expression for both WT FRU and IDH2 FRU groups compared to respective control 
groups, possibly due to small sample size and experimental variation (1.25 ± 0.109, p = 0.145; 
1.00 ± 0.109,  p = 0.138 for WT and IDH2 respectively). Of note, liver tissue mass was 
decreased in all IDH2 KO groups compared to respective counterpart groups which indicates 
impaired liver regeneration (p = 0.001 and 0.018 for IDH2 CON vs WT CON and IDH2 FRU vs 
WT FRU, respectively). Since hepatic TGs are used for liver tissue regeneration (27) this is 
somewhat in agreement with the DGAT2 expression data; for instance DGAT2 gene expression 
decreased, although it was not statistically significant, in IDH2 CON compared to the WT CON 
(approximately 25% reduction; 0.75 ± 0.109). Overall, gene expression patterns of SCD1, FAS, 
and DGAT2 were relatively consistent with liver mass phenotype as the expression levels of the 
genes tended to be lower in IDH2 KO mice compared to the WT mice, although SCD1 was the 
only gene which showed statistical significance (p < 0.05 for both WT and IDH2 groups; Figure 
3). 
 In addition to the lipogenesis pathway, expressions of genes involved in fatty acid β-
oxidation were examined. Fatty acids break down via fatty acid β-oxidation to acetyl-CoA and 
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function as cellular signaling molecules (28). In the present study, the mRNA expressions were 
measured of SIRT1, AMPKα, and PPAR-α, key genes in fatty acid β-oxidation. In recent studies, 
SIRT1 has been suggested in having a critical role in regulating lipid metabolism, as SIRT1 is an 
upstream regulator of SREBP-1 (key gene for lipogenesis and cholesterol synthesis) (29). 
Moreover, SIRT1 inhibits the expression of fat storage genes, thereby reducing TG accumulation. 
Additionally, AMPK is a sensor of cellular energy status, and is activated by a level of 
AMP/ATP or upstream kinases (30). Recent studies indicate SIRT1 positively regulates AMPK 
signaling through cell types such as hepatocytes (30). SIRT1 -dependent AMPK inhibits 
downstream regulators of AMPK, such as ACC and FAS, and reduces lipid accumulation 
through fatty acid β-oxidation (30). Therefore, SIRT1 and AMPK both have roles in regulating 
lipid metabolism, especially fatty acid oxidation. In addition to the connection with AMPK, 
SIRT1 positively regulates PPAR-α (31), which controls fatty acid β-oxidation (32) in which 
PPAR-α ligand binding leads to activation of fatty acid catabolism and oxidative degradation of 
fatty acid derivatives (32). In the study, no difference was shown in these three genes throughout 
the experimental groups (p > 0.05). However, SIRT1 and PPAR-α gene expression were not 
changed throughout the groups, which is puzzling to interpret (Figure 4). Further, the expression 
of AMPKα was unchanged by fructose intervention and IDH2 KO, which warrants validation by 
examining phosphorylation of AMPKα at threonine 172 (p > 0.05).  
 
VII. Future Directions 
 Limitations of the study expressed below can be address in future studies. First, as 
discussed above, obesity is closely related to production of ROS, which causes cellular damage 
and can initiate inflammatory signaling (33). In this study, however, ROS-related genes or 
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inflammatory markers (such as inflammatory cytokines or neutrophils, to examine if 
inflammation reactions were triggered within the liver in response to fructose intervention or 
IDH2 deficiency) were not measured. Studies show that inflammatory cytokines may lead to an 
accumulation of TGs and increase cellular oxidative stress (34). In turn, an increase of hepatic 
TGs results in more production of the cytokines such as tumor necrosis factor alpha and 
interleukin-6. These cytokines can generate more ROS and lead to lipid peroxidation (35, 36). 
Therefore, it would be interesting to see if inflammatory signaling was exacerbated by fructose 
intervention in IDH2 KO mice, possibly due to a dysregulated redox system. 
In addition to inflammation, the glutathione redox system is one of the most prominent 
antioxidant defense systems in protecting against oxidative damage in cells. Glutathione (GSH) 
is a key in repairing and preventing oxidative damage to lipids, proteins, and nucleic acids. If 
there is a reduction in GSH level and an increase in GSSG level (an oxidized form of 
glutathione), there could also be an increase in ROS and oxidative damage. Hence, NADPH 
supply is important as it produces reducing power to convert GSSG to GSH. Therefore, in future 
studies, there can be an examination if IDH2 deficient mice are more susceptible to oxidative 
damage due to their inability to provide sufficient NADPH in the TCA cycle in which a ratio of 
GSH/GSSH will be directly assessed. 
Even though key genes that are related to lipid metabolism were measured, four genes in 
lipogenesis and three genes in lipolysis, there are other genes involved in obesity and fat 
accumulation. For instance, in lipogenesis, LXR plays a significant role in metabolism of 
cholesterol and lipogenesis (37). LXR is an important transcription factor that is the main 
regulator of SREBP-1 in the synthesis of fatty acids (38). Additionally, measuring more genes 
involved in lipolysis, such as Peroxisome proliferator-activated receptor (PPAR-ɣ2), Fatty Acid 
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Binding Protein 4 (FABP4), and Lipoprotein lipase (LPL), could strengthen results in support of 
the phenotypes. PPAR-ɣ2, FABP4, and LPL are normally expressed in adipose tissue, and are 
associated with fatty acid oxidation (39). FABPs are a superfamily of lipid-binding proteins, and 
FABP5 is specifically associated with liver fat content. LPL functions as a rate limiting protein 
for TG particles rich in lipoprotein. LPL activity is high in the adipose tissue of obese humans 
(39). In future studies these genes could be examined to better explain phenotypes found in mice 
used in this experiment. 
Another limitation was the small sample size of this project. The tissue harvested was 
from a total of six mice per group, with intervention for six weeks. The small sample size may 
have played a factor in the inconclusive results. With a larger quantity of mice a larger pool of 
liver tissue could be utilized to test for further gene expression analyses. In addition, in the 
present study, there was no measurement of protein expression and enzymatic activity. In the 
future in addition to measuring mRNA, future studies could measure protein expression and 
enzymatic activity to determine any agreement with these mRNA expression data patterns. 
 
VIII. Conclusion  
 In this project, it was found that IDH2 deficiency aggravated fructose-induced obesity 
conditions hence, related hepatic gene expressions were examined. Specifically, visceral fat mass 
was significantly higher in IDH2 KO groups compared to the WT groups. In contrast, liver mass 
was decreased in IDH2 KO groups compared to WT groups. Although liver mass phenotype was 
generally in agreement with the lipogenesis gene expression results, due to the small sample size, 
it is difficult to draw a solid conclusion with limited statistical power. Thus further analyses will 
be required. 
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Abbreviations:  
Acetyl-Coenzyme A Carboxylase (ACC); AMP-activated Protein Kinase alpha (AMPKα); 
Adenosine Triphosphate (ATP); Diglyceride Acyltransferase 2 (DGAT2); Fatty Acid Binding 
Protein 4 (FABP4); Fatty Acid Synthase (FAS); Glutathione (GSH); Oxidized GSH (GSSG); 
Knockout (KO); Lipoprotein Lipase (LPL); Mitochondrial NADP+-dependent Isocitrate 
Dehydrogenase (IDH2); IDH2 KO Control (IDH2 CON); IDH2 KO Fructose  (IDH2 FRU); 
National Health and Nutrition Examination Survey (NHANES); Nicotinamide Adenine 
Dinucleotide Phosphate (NADP+); Nicotinamide Adenine Dinucleotide Phosphate, reduced 
(NADPH); Nonalcoholic Fatty Liver Disease (NAFLD); Peroxisome Proliferator-Activated 
Receptor-alpha (PPAR-α); PPAR-gamma2 (PPAR-ɣ2); Reactive Oxidative Species (ROS); 
Sirtuin 1 (SIRT1);  Stearoyl-CoA Desaturase 1 (SCD1); Sterol Regulatory Element-Binding 
Protein-1 (SREBP-1); Triglycerides (TG); Wild Type CON (WT CON). 
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XI. Tables and Figures  
Table 1. AIN-76A Purified Diet Formulation 
Ingredient g/kg 
Casein 200.00 
DL-Methionine 3.00 
Dyetrose -- 
Cornstarch 150.00 
Sucrose 500.00 
Cellulose 50.00 
Soybean Oil -- 
Corn Oil 50.00 
t-Butylhydroquinone -- 
Salt Mix #200000 35.00 
Salt Mix #210025 -- 
Salt Mix #210050 -- 
Vitamin Mix #300030 10.00 
Vitamin Mix #310025 -- 
L-Cystine -- 
Choline Bitartrate 2.00 
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Figure 1. Body weight gain was not changed by fructose intervention in mice.  
Data was expressed as least squares mean ± standard error of means. Statistical analysis was 
carried by one-way ANOVA followed by multiple comparisons using the difference matrix of 
least squares mean (SAS Institute, Cary, NC, USA). P-values less than 0.05 were considered 
statistically different. Sharing same superscript indicates no statistical difference. WT CON, 
Wild type mice fed control diet; WT FRU, Wild type mice fed fructose supplemented water 
(34% v/v); IDH2 CON, IDH2 KO mice fed control diet; IDH2 FRU, IDH2 mice fed fructose 
supplemented water (34% v/v). See the method section for detail experimental conditions. 
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Figure 2. Effects of fructose intervention and IDH2 deficiency on ratios of tissue weight to body 
weight.  
Data was expressed as least squares mean ± standard error of means. Statistical analysis was 
carried by one-way ANOVA followed by multiple comparisons using the difference matrix of 
least squares mean (SAS Institute, Cary, NC, USA). P-values less than 0.05 were considered 
statistically different. Sharing same superscript indicates no statistical difference. WT CON, 
Wild type mice fed control diet; WT FRU, Wild type mice fed fructose supplemented water 
(34% v/v); IDH2 CON, IDH2 KO mice fed control diet; IDH2 FRU, IDH2 mice fed fructose 
supplemented water (34% v/v). See the method section for detail experimental conditions. 
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Figure 3. Effects of fructose intervention and IDH2 deficiency on expression of hepatic 
lypogenesis genes. 
Data was expressed as least squares mean ± standard error of means. Statistical analysis was 
carried by one-way ANOVA followed by multiple comparisons using the difference matrix of 
least squares mean (SAS Institute, Cary, NC, USA). P-values less than 0.05 were considered 
statistically different. Sharing same superscript indicates no statistical difference. WT CON, 
Wild type mice fed control diet; WT FRU, Wild type mice fed fructose supplemented water 
(34% v/v); IDH2 CON, IDH2 KO mice fed control diet; IDH2 FRU, IDH2 mice fed fructose 
supplemented water (34% v/v). SREBP-1, Sterol Regulatory Element-Binding Protein-1; SCD1, 
Stearoyl-CoA Desaturase 1; FSA, Fatty Acid Synthase; DGAT2, Diglyceride Acyltransferase 2; 
See the method section for detail experimental conditions. 
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Figure 4. Effects of fructose intervention and IDH2 deficiency on hepatic expression of fatty 
acid oxidation genes. 
Data was expressed as least squares mean ± standard error of means. Statistical analysis was 
carried by one-way ANOVA followed by multiple comparisons using the difference matrix of 
least squares mean (SAS Institute, Cary, NC, USA). P-values less than 0.05 were considered 
statistically different. Sharing same superscript indicates no statistical difference. WT CON, 
Wild type mice fed control diet; WT FRU, Wild type mice fed fructose supplemented water 
(34% v/v); IDH2 CON, IDH2 KO mice fed control diet; IDH2 FRU, IDH2 mice fed fructose 
supplemented water (34% v/v). AMPKɑ, AMP-activated Protein Kinase alpha; SIRT1, Sirtuin 1; 
PPAR-ɑ, Peroxisome Proliferator-Activated Receptor-alpha; See the method section for detail 
experimental conditions. 
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